Previous 10 | Next 10 |
Swedish Orphan Biovitrum ( OTCPK:BIOVF ) (Sobi) signed a licensing agreement to develop and commercialize ADC Therapeutics' ( NYSE: ADCT ) Zynlonta (loncastuximab tesirine) for all blood and solid tumor indications outside the U.S., Greater China, Singapore and Ja...
ADC Therapeutics is eligible to receive up to $435 million, including $55 million upfront, $50 million on first European Commission approval and up to approximately $330 million in additional regulatory and sales milestones ADC Therapeutics to receive royalties from mid-teens ...
Ameet Mallik, Chief Executive Officer of ADC Therapeutics, also joins the Board ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of veteran oncology drug developer Jean-Pierre Bizzari, MD, to its Board of Directors. Additionally, Ameet Mallik, who was appoint...
ADC Therapeutics ( NYSE: ADCT ) said the first patient was dosed in a phase 1b trial of Zynlonta in combination with other anti-cancer agents in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). Zynlonta (loncastuximab tesirine-lpyl) is approved i...
Opportunity to enhance outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphoma First arm of trial to evaluate ZYNLONTA in combination with polatuzumab vedotin ADC Therapeutics SA (NYSE: ADCT) today announced the first patient has been dosed in LO...
Seasoned life sciences executive brings extensive business development expertise ADC Therapeutics SA (NYSE: ADCT) announced today it has appointed industry veteran David Gilman to the new role of Chief Business & Strategy Officer reporting to Chief Executive Officer Amee...
Overall response rate of 70.1% and complete response rate of 33.3% in heavily pretreated patients; median duration of response of 13.7 months Safety profile substantially consistent with prior findings Preparing for potential submission of a Biologics License Applicati...
ADC Therapeutics SA (NYSE: ADCT) announced today that its Chief Executive Officer, Ameet Mallik, will be participating in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 9:00 am ET. A live webcast of the presentation will be available via the Ev...
Oral presentation of pivotal Phase 2 clinical trial of Cami in relapsed or refractory Hodgkin lymphoma ZYNLONTA® diffuse large B-cell lymphoma data highlighted in several abstracts ADC Therapeutics SA (NYSE: ADCT), announced today that results from the pivotal P...
ADC Therapeutics (NYSE:ADCT) said on May 9 that Co-Founder Chris Martin stepped down as CEO and the company appointed Ameet Mallik to replace him in the role. Mallik served for 16 years at Novartis (NVS), most recently as executive vice president and Head of U.S. Oncology. ADC ...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...